Abstract：Objective To provide evidence-based evidence for the choice of drugs for clinical treatment of depression and to evaluate the economics. Methods CNKI, WanFang, VIP, PubMed, EMBase, Cochrane library and SinoMed were all searched. Randomized controlled trials of Paroxetine and Duloxetine in the treatment of depression were screened, the retrieval time was set up until March 2020. Meta-analysis and pharmacoeconomic analysis were performed using RevMan 5.3 software and cost-effectiveness ratio. Results A total of 12 RCT articles, 1722 patients were included in the analysis. Meta-analysis results showed that there was no significant difference in the total effective rate between the two groups in treating depression (RR = 1.01, 95%CI [0.96, 1.07], P = 0.65), after treatment, there was a statistically significant difference in the score of hamilton depression scale between the two groups (MD = 0.71, 95%CI [0.25, 1.17], P = 0.003), and there was a statistically significant difference in the adverse reactions between the two groups (RR = 1.11, 95%CI [1.01, 1.21], P = 0.02), and both groups were well tolerated. In terms of pharmacoeconomics, the cost-effectiveness ratio of paroxetine was 371.21 and the duloxetine was 536.11, incremental cost-effectiveness ratio was -28 431.03. Conclusion Paroxetine and Duloxetine have similar clinical effects in the treatment of depression, and paroxetine is more prone to adverse reactions, and paroxetine has economic advantages.
陈幸 王晓莉. 帕罗西汀对比度洛西汀治疗抑郁症的系统评价及药物经济学分析[J]. 中国医药导报, 2021, 18(9): 140-144.
CHEN Xing WANG Xiaoli. Systematic evaluation and pharmacoeconomic analysis of Paroxetine versus Duloxetine in treatment of depression. 中国医药导报, 2021, 18(9): 140-144.
2021, Vol. 18 
京公网安备 11010502046598号